comparemela.com
Home
Live Updates
Spironolactone Misses Mark in Hemodialysis Trial : comparemela.com
Spironolactone Misses Mark in Hemodialysis Trial
Primary results presented at ASN Kidney Week 2023 showed spironolactone missed the trial's primary endpoint.
Related Keywords
Belgium
,
Monaco
,
France
,
United States
,
American
,
Boehringer Ingelheim Patrick Rossignol
,
Zannadf Massy
,
Patrick Rossignol
,
Monaco Private Haemodialysis Centre
,
American Society Of Nephrology Kidney Week
,
Boehringer Ingelheim
,
Antagonist Chronic
,
Interventional Survival Trial
,
American Society
,
Nephrology Kidney Week
,
Princess Grace Hospital
,
Paper Presented
,
Coral Route
,
Phase 3
,
Trial
,
Study
,
Alchemist
,
Aldosterone
,
Spironolactone
,
Chronic Kidney Disease
,
Ckd
,
Hemodialysis
,
Comorbidity
,
Cardiovascular
,
Hospitalization
,
comparemela.com © 2020. All Rights Reserved.